BridgeBio Pharma (BBIO) Non-Current Assets (2018 - 2026)

BridgeBio Pharma has reported Non-Current Assets for 9 years, with the latest figure at $129.7 million in Q1 2026.

• Quarterly Non-Current Assets fell 30.46% year-over-year to $129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $594.7 million (down 24.11% YoY) and the FY2025 annual result came in at $138.3 million, down 30.39% from the prior year.
• Non-Current Assets fell to $129.7 million in Q1 2026 per BBIO's latest filing, from $138.3 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $220.4 million in Q3 2024 and troughed at $65.9 million in Q1 2024.
• A 5-year average of $121.9 million and a median of $96.9 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets sank 47.0% in 2022, then surged 227.3% in 2024.
• Over 5 years, Non-Current Assets stood at $74.2 million in 2022, then slipped by 7.27% to $68.8 million in 2023, then soared by 188.78% to $198.6 million in 2024, then slumped by 30.39% to $138.3 million in 2025, then dropped by 6.22% to $129.7 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $129.7 million, $138.3 million, and $158.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.